Cargando…

Non-Invasive markers for hepatic fibrosis

With great advancements in the therapeutic modalities used for the treatment of chronic liver diseases, the accurate assessment of liver fibrosis is a vital need for successful individualized management of disease activity in patients. The lack of accurate, reproducible and easily applied methods fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baranova, Ancha, Lal, Priyanka, Birerdinc, Aybike, Younossi , Zobair M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176189/ https://www.ncbi.nlm.nih.gov/pubmed/21849046 http://dx.doi.org/10.1186/1471-230X-11-91

Ejemplares similares

Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C)
por: Birerdinc, Aybike, et al.
Publicado: (2012)

Knowledge-Based Identification of Soluble Biomarkers: Hepatic Fibrosis in NAFLD as an Example
por: Page, Sandra, et al.
Publicado: (2013)

The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin
por: Younossi, Zobair M, et al.
Publicado: (2012)

Validation of endogenous reference genes for qRT-PCR analysis of human visceral adipose samples
por: Mehta, Rohini, et al.
Publicado: (2010)

Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS)
por: Baranova, Ancha, et al.
Publicado: (2013)

Expression of energy metabolism related genes in the gastric tissue of obese individuals with non-alcoholic fatty liver disease
por: Mehta, Rohini, et al.
Publicado: (2014)

Expression of Inflammation-Related Genes Is Altered in Gastric Tissue of Patients with Advanced Stages of NAFLD
por: Mehta, Rohini, et al.
Publicado: (2013)

KPP: KEGG Pathway Painter
por: Manyam, Ganiraju, et al.
Publicado: (2015)

Age-independent rise of inflammatory scores may contribute to accelerated aging in multi-morbidity
por: Stepanova, Maria, et al.
Publicado: (2015)

Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects
por: Mehta, Rohini, et al.
Publicado: (2014)

The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH)
por: Mehta, Rohini, et al.
Publicado: (2016)

Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH)
por: Mehta, Rohini, et al.
Publicado: (2018)

Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region
por: Birerdinc, Aybike, et al.
Publicado: (2009)

An exploratory study examining how nano-liquid chromatography–mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease
por: Younossi, Zobair M., et al.
Publicado: (2018)

Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
por: Sayiner, Mehmet, et al.
Publicado: (2018)

Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma
por: Younossi, Zobair M., et al.
Publicado: (2021)

Pediatric Non-Alcoholic Fatty Liver Disease
por: Bush, Haley, et al.
Publicado: (2017)

Markers of arterial health could serve as accurate non-invasive predictors of human biological and chronological age
por: Fedintsev, Alexander, et al.
Publicado: (2017)

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens
por: Younossi, Zobair M., et al.
Publicado: (2016)

Hepatic steatosis and fibrosis: Non-invasive assessment
por: Karanjia, Rustam N, et al.
Publicado: (2016)

Nonalcoholic steatohepatitis: global impact and clinical consequences
por: Kabarra, Khaled, et al.
Publicado: (2021)

PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes
por: Baranova, Ancha
Publicado: (2008)

Non-invasive serum fibrosis markers: A study in chronic hepatitis
por: Abdollahi, Mohammadreza, et al.
Publicado: (2015)

PPARγ activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFβ signalling
por: Jarrar, Mohammed H, et al.
Publicado: (2007)

Development and validation of a primary sclerosing cholangitis-specific health-related quality of life instrument: CLDQ-PSC
por: Younossi, Zobair M., et al.
Publicado: (2023)

Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease
por: Younossi, Zobair M., et al.
Publicado: (2021)

Are non‐invasive fibrosis markers for chronic hepatitis B reliable in sub‐Saharan Africa?
por: Desalegn, Hailemichael, et al.
Publicado: (2017)

Should adults with diabetes mellitus be vaccinated against hepatitis B virus? A systematic review of diabetes mellitus and the progression of hepatitis B disease
por: Younossi, Zobair, et al.
Publicado: (2017)

Fibrosis‐4 Index as an Independent Predictor of Mortality and Liver‐Related Outcomes in NAFLD
por: Vieira Barbosa, Joana, et al.
Publicado: (2021)

Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B
por: Buti, Maria, et al.
Publicado: (2021)

Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials
por: Younossi, Zobair, et al.
Publicado: (2017)

Non-Invasive Indirect Markers of Liver Fibrosis after Interferon-Free Treatment for Hepatitis C
por: Przekop, Dagmara, et al.
Publicado: (2021)

Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor
por: Stepanova, Maria, et al.
Publicado: (2016)

Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States
por: Golabi, Pegah, et al.
Publicado: (2016)

Importance of fatigue and its measurement in chronic liver disease
por: Gerber, Lynn H, et al.
Publicado: (2019)

Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review
por: Rinaldi, Luca, et al.
Publicado: (2023)

The Association between Non-Invasive Hepatic Fibrosis Markers and Cardiometabolic Risk Factors in the Framingham Heart Study
por: Long, Michelle T., et al.
Publicado: (2016)

Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B
por: Montazeri, Ghodrat, et al.
Publicado: (2005)

Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care
por: Younossi, Zobair M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k0mqtc67ftjttkfdorqe2i7p7b